O-12 The cost effectiveness (CE) and cost to medicare of gefitinib (Iressa; ZD1839) for the third-line treatment of non-small cell lung cancer (NSCLC): Can medicare afford the bill?

✍ Scribed by Roberts, Thomas Gerald; Lynch, Thomas James

• Book ID: 118571403
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 339 KB
• Volume: 41
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/s0169-5002(03)91670-9